- Report
- March 2025
- 285 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- July 2024
- 145 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- November 2023
- 175 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- December 2023
- 115 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 181 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2022
- 44 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- May 2022
- 39 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Edema Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat edema, a condition characterized by swelling due to fluid accumulation in the body's tissues. These drugs are used to reduce swelling and improve symptoms such as pain, discomfort, and difficulty breathing. Commonly used edema drugs include diuretics, which reduce the amount of fluid in the body, and vasodilators, which relax the blood vessels and reduce swelling. Other drugs used to treat edema include ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers.
The Edema Drug market is highly competitive, with many companies offering a variety of drugs to treat edema. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies in the market include AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more